A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the tolerability and safety of valsartan in patients with stable,
chronic heart failure (NYHA Class ll-lll). The 12-week double blind study has a 2-week
(maximum) screening, and a 10-week active treatment phase. In each of the treatment arms (QD
and BID), patients are up-titrated to a maximum valsartan total daily dose of 320 mg.
Patients remain on their prior CHF standard care therapy throughout the study period, and the
up-titration of valsartan is based on patient tolerability.